Literature DB >> 28693172

Silencing platelet-derived growth factor receptor-β enhances the radiosensitivity of C6 glioma cells in vitro and in vivo.

Ji-Dong Hong1,2, Xia Wang1, Yu-Ping Peng1, Jiang-Hua Peng1, Jun Wang2, Ye-Ping Dong2, Dan He2, Zhen-Zi Peng2, Qing-Song Tu1, Liang-Fang Sheng1, Mei-Zuo Zhong1, Chao-Jun Duan2,3.   

Abstract

Platelet-derived growth factor receptor (PDGFR)-β is an important tyrosine kinase and its downregulation has been reported to alter the radiosensitivity of glioma cells, although the underlying mechanism is unclear. In order to investigate the effect of PDGFR-β on the radiosensitivity of glioblastoma, the present study transfected C6 glioma cells with a PDGFR-β-specific small interfering (si)RNA expression plasmid, and downregulation of the expression of PDGFR-β in C6 glioma cells was confirmed by western blotting and immunohistochemical analysis. Clone formation assays and xenograft growth curves demonstrated that PDGFR-β-siRNA enhanced the radiosensitivity of C6 glioma cells in vitro and in vivo. Furthermore, MTT and xenograft growth curves demonstrated that PDGFR-β-siRNA inhibited the proliferation of C6 glioma cells in vitro and in vivo, and terminal deoxynucleotidyl transferase dUTP nick end-labeling and immunohistochemical analyses demonstrated that PDGFR-β-siRNA induced apoptosis and inhibited the expression of Ki-67, cyclin B1 and vascular endothelial growth factor in C6 glioma cell xenografts. Taken together, these results suggested that PDGFR-β may be used as a target for the radiosensitization of glioblastoma.

Entities:  

Keywords:  RNA interference; glioblastoma; platelet-derived growth factor receptor-β; radiosensitization

Year:  2017        PMID: 28693172      PMCID: PMC5494875          DOI: 10.3892/ol.2017.6143

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.

Authors:  Jeffery S Russell; Kristin Brady; William E Burgan; Michael A Cerra; Kelli A Oswald; Kevin Camphausen; Philip J Tofilon
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

Review 2.  [Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].

Authors:  E Cohen-Jonathan Moyal
Journal:  Cancer Radiother       Date:  2009-08-19       Impact factor: 1.018

Review 3.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

4.  Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation.

Authors:  M Hermansson; M Nistér; C Betsholtz; C H Heldin; B Westermark; K Funa
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

5.  Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance.

Authors:  M Maxwell; S P Naber; H J Wolfe; T Galanopoulos; E T Hedley-Whyte; P M Black; H N Antoniades
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas.

Authors:  K H Plate; G Breier; C L Farrell; W Risau
Journal:  Lab Invest       Date:  1992-10       Impact factor: 5.662

Review 8.  Antiangiogenics and radiotherapy.

Authors:  Aoife M Shannon; Kaye J Williams
Journal:  J Pharm Pharmacol       Date:  2008-08       Impact factor: 3.765

9.  Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.

Authors:  Huan Ren; Xiaoqing Tan; Yucui Dong; Alf Giese; Ting Chao Chou; Nikolai Rainov; Baofeng Yang
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-01-21       Impact factor: 4.080

10.  miR-34a regulates mesangial cell proliferation via the PDGFR-β/Ras-MAPK signaling pathway.

Authors:  Dapeng Chen; Ying Li; Yan Mei; Wenjia Geng; Jurong Yang; Quan Hong; Zhe Feng; Guangyan Cai; Hanyu Zhu; Suozhu Shi; Xue-Yuan Bai; Xiangmei Chen
Journal:  Cell Mol Life Sci       Date:  2014-03-18       Impact factor: 9.261

View more
  1 in total

Review 1.  Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments.

Authors:  Vilashini Rajaratnam; Mohammad Mohiminul Islam; Maixee Yang; Rachel Slaby; Hilda Martinez Ramirez; Shama Parveen Mirza
Journal:  Cancers (Basel)       Date:  2020-04-10       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.